Callan Capital LLC boosted its position in Sanofi (NASDAQ:SNY – Free Report) by 90.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 9,852 shares of the company’s stock after purchasing an additional 4,685 shares during the period. Callan Capital LLC’s holdings in Sanofi were worth $478,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UBS Group AG raised its stake in shares of Sanofi by 5.1% during the 4th quarter. UBS Group AG now owns 934,635 shares of the company’s stock worth $46,479,000 after purchasing an additional 45,175 shares during the period. Corient Private Wealth LLC raised its position in Sanofi by 62.1% in the fourth quarter. Corient Private Wealth LLC now owns 169,494 shares of the company’s stock worth $8,429,000 after acquiring an additional 64,949 shares during the period. Assetmark Inc. boosted its stake in Sanofi by 7.1% in the fourth quarter. Assetmark Inc. now owns 84,426 shares of the company’s stock valued at $4,199,000 after acquiring an additional 5,578 shares during the last quarter. Frazier Financial Advisors LLC bought a new position in shares of Sanofi during the 4th quarter valued at approximately $28,000. Finally, Cypress Asset Management Inc. TX purchased a new stake in shares of Sanofi during the 4th quarter worth approximately $508,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.
Sanofi Price Performance
Sanofi stock opened at $57.63 on Friday. The firm has a market capitalization of $145.96 billion, a P/E ratio of 28.96, a PEG ratio of 1.62 and a beta of 0.60. Sanofi has a one year low of $42.63 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business has a fifty day moving average price of $54.34 and a 200-day moving average price of $50.48.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Friday. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.
Check Out Our Latest Analysis on SNY
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
- Five stocks we like better than Sanofi
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Bank Stocks – Best Bank Stocks to Invest In
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.